skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Emerging treatments in the management of bipolar disorder – focus on risperidone long acting injection

Review

(3403) Views  (680) Full article downloads

Authors: Wissam El-Hage, Simon A Surguladze

Published Date July 2010 Volume 2010:6(1) Pages 455 - 464
DOI: http://dx.doi.org/10.2147/NDT.S7608

Wissam El-Hage1, Simon A Surguladze2

1Inserm U930 ERL CNRS 3106, Université François Rabelais and Clinique Psychiatrique Universitaire, CHRU de Tours, Tours, France; 2Institute of Psychiatry, King’s College London, UK

Abstract: Bipolar disorder is a life-long psychiatric illness characterized by a high frequency of relapses and substantial societal costs. Almost half of the patients are prescribed second generation antipsychotics for treatment of manic states, or as the maintenance therapy. ­Risperidone long acting injection (RLAI) as a monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder was approved by Food and Drug Administration (FDA) in United States in May 2009. In this review we will consider the aspects of pharmacology, pharmacokinetics, metabolism, safety and tolerability, and clinical trials focusing on the efficacy of RLAI in bipolar disorder. The patients’ perspective and attitudes to long-acting injections will also be discussed.

Keywords: second generation, antipsychotics, patient attitudes, lithium, valproate, monotherapy






Readers of this article also read: